Immunic to Participate in Investor and Scientific Conferences in March
-
March 11-13 :Leerink Partners Global Biopharma Conference .Daniel Vitt , Ph.D., Chief Executive Officer and President ofImmunic , andJessica Breu , Vice President Investor Relations and Communications, will participate in one-on-one investor meetings at this conference inMiami, FL. -
March 17-20 : Frontiers in Medicinal Chemistry. Two abstracts have been accepted for poster presentations at this conference inMunich, Germany . The poster presentations will be accessible on the "Events and Presentations" section ofImmunic's website at: https://ir.imux.com/events-and-presentations.- Poster Title: Characterisation of Dual Nurr1 Activator/DHODH Inhibitor Vidofludimus Calcium and Development Towards a Nurr1 Selective Tool Compound
- Presenting Author: Christian Gege, Ph.D., Head of Intellectual Property at
Immunic - Abstract ID: 11632_36356
- Poster Board Number: P039
- Poster Title: Characterizing the Effects of NR4A Agonism in Neuroinflammation In Vitro
- Presenting Author:
Romy Busch ,Department of Pharmacy ,Center for Pharmaceutical Research , Ludwig-Maximilians-University of Munich - Abstract ID: 11632_36404
- Poster Board Number: P072
The posters will be presented during the whole conference. Poster sessions are planned as following:
-
- Poster session I:
Sunday, March 17, 2024 , 6:00 –10:00 pm CET - Poster session II:
Monday, March 18, 2024 , 5:00 –7:00 pm CET
- Poster session I:
-
March 25-28 : 33rd Annual Meeting of theSociety for Virology . Two abstracts have been accepted for poster and oral presentations at this conference inVienna, Austria . The presentations will be accessible on the "Events and Presentations" section ofImmunic's website at: https://ir.imux.com/events-and-presentations.- Poster Presentation: Preclinical Development of Host-Directed Dual-Target Small Molecule Inhibitors as Broad-Spectrum Antivirals
- Presenting Author:
Alexandra Herrmann , Ph.D., Manager Translational Pharmacology,Immunic - Abstract ID Number: 107
- Program ID: P 078
- Poster Session: Antiviral Therapy and Resistance
- Date:
Monday, March 25, 2024 - Time:
1:00 pm CET - Abstract Title: Characterization of Mpox Virus Genomes and Patient Isolates From Franconia (
Bavaria, Germany ) and Antiviral Testing of Patient Isolates - Presenting Author: Arne Cordsmeier, Ph.D.,
Institute of Clinical and Molecular Virology , University Hospital Erlangen - Abstract ID: 73
- Program ID: O 106
- Oral Presentation Session: Antiviral Therapy and Resistance 2
- Date:
Thursday, March 28, 2024 - Time: 11:00 –
11:15 am CET
About
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and scientific conferences.
Contact Information
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
+1 917 633 7790
immunic@rxir.com
US Media Contact
KOGS Communication
+1 617 974 8659
kaplan@kogspr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-investor-and-scientific-conferences-in-march-302082729.html
SOURCE